CAUTIONFEDGLP-1 Compounding2025-08-13

FDA recall (Class II): Tirzepatide + Niacinamide 13.2 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, …

FDA recalls compounded GLP-1 product due to processing controls issue.

What to do

Free

Enter your email to unlock “What to do” on every alert — and get the weekly Brief. No charge.

Want it filtered to YOUR states + real-time alerts? Become a member →

FDA Enforcement · primary source ↗

Related alerts

Monitoring, not legal advice.